![]() Patients with MCI are often the target populations for candidate drugs and other AD clinical trials, although there has been little success in reversing what cognitive impairment already exists. It is well-known that the onset of AD is preceded by 5–10 years of subtle cognitive decline which may be noticed by individuals or their family members but is often compensated for until a diagnosis of mild cognitive impairment (MCI) is made and the individual has lost independence. With the rapidly aging populations in the United States and Europe, the expected number of people living with dementia at any stage by 2050 is expected to be at 152.8 million ( GBD 2019 Dementia Forecasting Collaborators, 2019). Considering predementia stages, the number of people with AD is much larger than conveyed in available literature ( Gustavsson et al., 2022). Together this constitutes 416 million across the AD continuum, or 22% of all individuals aged 50 and above. The global number of individuals with Alzheimer's disease (AD) including dementia, prodromal, and preclinical stages, is estimated at 32, 69, and 315 million, respectively. Mobile applications and use of ML is widely considered a financially and socially viable method of compiling symptomatic data but currently this large potential dataset, screening tool, and research resource is still largely untapped. Concerns about the validity of mobile apps for cognitive screening and privacy issues remain prevalent. We found that although data collecting cognition-related apps have existed for years, the use of these apps as screening tools remains underdeveloped however, it may serve as proof of concept and feasibility as there is much supporting evidence on their predictive utility. Many publications were excluded because they focused on apps which fail to collect data and simply provide users with cognitive health information. We identified relevant literature ( n = 25) which fit our criteria. Criteria for inclusion was limited to articles in English which referenced data collection via mobile app from adults 50+ concerned, at risk of, or diagnosed with AD dementia. Additional literature published in 2023 was accounted for with a follow-up search prior to publication. ![]() The initial search deadline was December 1, 2022. The PubMed database was searched to identify existing literature on apps related to dementia and cognitive health data collection. This review comments on existing evidence of mobile device applications designed to passively and/or actively collect data on cognition relevant for early detection and diagnosis of Alzheimer's disease (AD). ![]() Data logged or tracked in an app and analyzed with machine learning (ML) could identify subtle cognitive changes and lead to more timely diagnoses on an individual and population level. There is a growing opportunity for users to share the data collected with their medical providers which may serve as an accessible cognitive impairment screening tool. Smart mobile phone use is increasing worldwide, as is the ability of mobile devices to monitor daily routines, behaviors, and even cognitive changes. 3Department of Neurology, University Hospital Hradec Králové, Faculty of Medicine, Charles University, Hradec Králové, Czechia.2Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czechia.1Augusta University/University of Georgia Medical Partnership, Medical College of Georgia, Athens, GA, United States.Lydia Piendel 1,2 * Martin Vališ 3 Jakub Hort 2
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |